Lonza’s shares fell almost 7% on news the CEO would depart at the end of September, which RBC described as unexpected and was unlikely to provide the market with confidence heading into next month’s capital-markets day.
The Federal Trade Commission reached a settlement with Amgen that would allow the drugmaker to acquire Horizon Therapeutics and dismisses the antitrust claims of six states.
VinFast, the Vietnamese electric-vehicle maker, and Arm, a British chip designer, are caught in a weird limbo thanks to their decisions on where to list their shares.